Arkeon backs NOVACYT

Arkeon contributed around €600,000 to the round. The investment was made through the Arkeon pre-IPO 2011 retail vehicle, which closed on €10m in 2011.

Private investors provided co-investment. The capital increase will underpin the firm's international expansion.

Company
Founded in 2006 and based in Vélizy, NOVACYT designs and develops open and applied solutions in liquid-based cytology. The firm operates in the collection and preservation of cell samples and aims to improve the analysis and diagnosis in screening for cervical cancer. More than a million tests have already been completed using the firm's technology, which allows for the single extraction of cells from the tip of a brush using a cell extraction filter system. The system reduces the risk of infection and aerosolisation of extracted cells.

NOVACYT markets its system in more than 10 countries and has an installed base of more than 60 instruments.

People
Managing partner Arnaud Filhol and associate Emile Parte led the transaction for Arkeon.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Healthcare
• Expansion
• France